Drug Trial Radar · NCT05734105
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.
Conditions
- GIST
Interventions
RipretinibDrug
50 mg tablets
SunitinibDrug
12.5 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to end of treatment; up to approximately 48 months
Locations
70 sites in 15 countries. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
Yale University
New Haven, Connecticut
Mayo Clinic Florida
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Johns Hopkins Hospital
Baltimore, Maryland
Boston Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center
New York, New York
Cleveland Clinic
Cleveland, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virginia
Charlottesville, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Prince of Wales Hospital
Randwick, New South Wales, Australia
Alfred Health
Melbourne, Victoria, Australia
INCA - Instituto Nacional de Cancer
Rio de Janeiro, Rio de Janeiro, Brazil
CEPEN - Centro de Pesquisa e Ensino em Saude de Santa Catarina
Florianópolis, Santa Catarina, Brazil
Hospital de Cancer de Barretos - Fundacao Pio XII
Barretos, São Paulo, Brazil
Hospital Sirio-Libanes
São Paulo, São Paulo, Brazil
Hospital 9 de Julho
São Paulo, São Paulo, Brazil
AC Camargo Câncer Center
São Paulo, São Paulo, Brazil
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Clínica San Carlos De Apoquindo Red Salud UC Christus
Las Condes, RM, Chile
Centro de Oncología de Precisión
Santiago, RM, Chile
Institut Bergonié
Bordeaux, France
Centre Léon Bérard
Lyon, France
Institut Gustave Roussy
Villejuif, France
CHU Dijon
Dijon, Bourgogone, France
Centre Eugène Marquis
Rennes, Ille et Vilaine, France
Helios Klinikum Berlin-Buch
Berlin, Germany
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.